Literature DB >> 17634878

Direct comparison study between FDG-PET and IMP-SPECT for diagnosing Alzheimer's disease using 3D-SSP analysis in the same patients.

Takashi Nihashi1, Hiroshi Yatsuya, Kazumasa Hayasaka, Rikio Kato, Shoji Kawatsu, Yutaka Arahata, Katsushige Iwai, Akinori Takeda, Yukihiko Washimi, Kumiko Yoshimura, Kanako Mizuno, Takashi Kato, Shinji Naganawa, Kengo Ito.   

Abstract

PURPOSE: The purpose of this study was to evaluate and compare the diagnostic ability of 2-[(18)F]-fluoro-2-deoxy-D: -glucose (FDG) positron emission tomography (PET) and N-isopropyl-p-(123)I iodoamphetamine single photon emission computed tomography (IMP-SPECT) using three-dimensional stereotactic surface projections (3D-SSP) in patients with moderate Alzheimer's disease (AD).
MATERIALS AND METHODS: FDG-PET and IMP-SPECT were performed within 3 months in 14 patients with probable moderate AD. Z-score maps of FDG-PET and IMP-SPECT images of a patient were obtained by comparison with data obtained from control subjects. Four expert physicians evaluated and graded the glucose hypometabolism and regional cerebral blood flow (rCBF), focusing in particular on the posterior cingulate gyri/precunei and parietotemporal regions, and determined the reliability for AD. Receiver operating characteristic (ROC) curves were applied to the results for clarification. To evaluate the correlation between two modalities, the regions of interest (ROIs) were set in the posterior cingulate gyri/precunei and parietotemporal region on 3D-SSP images, and mean Z-values were calculated.
CONCLUSION: No significant difference was observed in the area under the ROC curve (AUC) between FDG-PET and IMP-SPECT images (FDG-PET 0.95, IMP-SPECT 0.94). However, a significant difference (P < 0.05) was observed in the AUC for the posterior cingulate gyri/precuneus (FDG-PET 0.94, IMP-SPECT 0.81). The sensitivity and specificity of each modality were 86%, and 97% for FDG-PET and 70% and 100% for IMP-SPECT. We could find no significant difference between FDG-PET and IMP-SPECT in terms of diagnosing moderate AD using 3D-SSP. There was a high correlation between the two modalities in the parietotemporal region (Spearman's r = 0.82, P < 0.001). The correlation in the posterior cingulate gyri/precunei region was lower than that in the parietotemporal region (Spearman's r = 0.63, P < 0.016).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17634878     DOI: 10.1007/s11604-007-0132-8

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  26 in total

1.  Low cerebral glucose extraction rates in the human medial temporal cortex and cerebellum.

Authors:  S Sakamoto; K Ishii
Journal:  J Neurol Sci       Date:  2000-01-01       Impact factor: 3.181

2.  Voxel- and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment.

Authors:  Chaorui Huang; Lars-Olof Wahlund; Ove Almkvist; Dagmawi Elehu; Leif Svensson; Tomas Jonsson; Bengt Winblad; Per Julin
Journal:  Neuroimage       Date:  2003-07       Impact factor: 6.556

3.  Diagnosis of suspected Alzheimer's disease is improved by automated analysis of regional cerebral blood flow.

Authors:  Bich-Ngoc-Thanh Tang; Satoshi Minoshima; Jean George; Annie Robert; Christian Swine; Patrice Laloux; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-01       Impact factor: 9.236

4.  Three-dimensional stereotactic surface projection of brain perfusion SPECT improves diagnosis of Alzheimer's disease.

Authors:  Norinari Honda; Kikuo Machida; Tohru Matsumoto; Hiroshi Matsuda; Etsuko Imabayashi; Jun Hashimoto; Makoto Hosono; Yusuke Inoue; Kiyoshi Koizum; Shigeru Kosuda; Toshimitsu Momose; Yutaka Mori; Motoo Oshima
Journal:  Ann Nucl Med       Date:  2003-12       Impact factor: 2.668

5.  Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and mild cognitive impairment: metabolic index and perfusion index.

Authors:  Natascha Döbert; Johannes Pantel; Lutz Frölich; Nadja Hamscho; Christian Menzel; Frank Grünwald
Journal:  Dement Geriatr Cogn Disord       Date:  2005-05-20       Impact factor: 2.959

Review 6.  Clinical application of positron emission tomography for diagnosis of dementia.

Authors:  Kazunari Ishii
Journal:  Ann Nucl Med       Date:  2002-12       Impact factor: 2.668

7.  Superiority of 3-dimensional stereotactic surface projection analysis over visual inspection in discrimination of patients with very early Alzheimer's disease from controls using brain perfusion SPECT.

Authors:  Etsuko Imabayashi; Hiroshi Matsuda; Takashi Asada; Takashi Ohnishi; Shigeki Sakamoto; Seigo Nakano; Tomio Inoue
Journal:  J Nucl Med       Date:  2004-09       Impact factor: 10.057

8.  Positron emission tomography in Alzheimer's disease.

Authors:  R Duara; C Grady; J Haxby; M Sundaram; N R Cutler; L Heston; A Moore; N Schlageter; S Larson; S I Rapoport
Journal:  Neurology       Date:  1986-07       Impact factor: 9.910

9.  Quantitative mapping of regional cerebral blood flow using iodine-123-IMP and SPECT.

Authors:  H Iida; H Itoh; M Nakazawa; J Hatazawa; H Nishimura; Y Onishi; K Uemura
Journal:  J Nucl Med       Date:  1994-12       Impact factor: 10.057

Review 10.  Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia.

Authors:  Nadine J Dougall; Sjoerd Bruggink; Klaus P Ebmeier
Journal:  Am J Geriatr Psychiatry       Date:  2004 Nov-Dec       Impact factor: 4.105

View more
  8 in total

1.  Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier.

Authors:  Dawn C Matthews; Ana S Lukic; Randolph D Andrews; Miles N Wernick; Stephen C Strother; Mark E Schmidt
Journal:  Alzheimers Dement (N Y)       Date:  2022-07-08

2.  Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis.

Authors:  Liping Fu; Linwen Liu; Jinming Zhang; Baixuan Xu; Yong Fan; Jiahe Tian
Journal:  Eur Radiol       Date:  2014-08-06       Impact factor: 5.315

3.  Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases.

Authors:  Sonja Daerr; Matthias Brendel; Christian Zach; Erik Mille; Dorothee Schilling; Mathias Johannes Zacherl; Katharina Bürger; Adrian Danek; Oliver Pogarell; Andreas Schildan; Marianne Patt; Henryk Barthel; Osama Sabri; Peter Bartenstein; Axel Rominger
Journal:  Neuroimage Clin       Date:  2016-10-08       Impact factor: 4.881

4.  Brain Network Alterations in Alzheimer's Disease Identified by Early-Phase PIB-PET.

Authors:  Liping Fu; Linwen Liu; Jinming Zhang; Baixuan Xu; Yong Fan; Jiahe Tian
Journal:  Contrast Media Mol Imaging       Date:  2018-01-08       Impact factor: 3.161

Review 5.  Brain SPECT as a Biomarker of Neurodegeneration in Dementia in the Era of Molecular Imaging: Still a Valid Option?

Authors:  Rodolfo Ferrando; Andres Damian
Journal:  Front Neurol       Date:  2021-05-10       Impact factor: 4.003

Review 6.  Clinical, biological, and imaging features of monogenic Alzheimer's Disease.

Authors:  Andrea Pilotto; Alessandro Padovani; Barbara Borroni
Journal:  Biomed Res Int       Date:  2013-11-27       Impact factor: 3.411

7.  Usefulness of 3-dimensional stereotactic surface projection FDG PET images for the diagnosis of dementia.

Authors:  Jahae Kim; Sang-Geon Cho; Minchul Song; Sae-Ryung Kang; Seong Young Kwon; Kang-Ho Choi; Seong-Min Choi; Byeong-Chae Kim; Ho-Chun Song
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

8.  Support vector machine-based classification of neuroimages in Alzheimer's disease: direct comparison of FDG-PET, rCBF-SPECT and MRI data acquired from the same individuals.

Authors:  Luiz K Ferreira; Jane M Rondina; Rodrigo Kubo; Carla R Ono; Claudia C Leite; Jerusa Smid; Cassio Bottino; Ricardo Nitrini; Geraldo F Busatto; Fabio L Duran; Carlos A Buchpiguel
Journal:  Braz J Psychiatry       Date:  2017-10-02       Impact factor: 2.697

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.